Jonathan Wolleben
Stock Analyst at Citizens
(4.57)
# 220
Out of 5,182 analysts
246
Total ratings
53.09%
Success rate
26.8%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Reiterates: Market Outperform | $132 | $92.01 | +43.47% | 15 | Apr 21, 2026 | |
| DBVT DBV Technologies | Maintains: Market Outperform | $45 → $47 | $19.50 | +141.03% | 17 | Mar 27, 2026 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $29 → $28 | $18.79 | +49.02% | 7 | Mar 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $152 → $155 | $85.70 | +80.86% | 9 | Mar 20, 2026 | |
| SPRB Spruce Biosciences | Maintains: Market Outperform | $180 → $170 | $54.21 | +213.60% | 10 | Mar 10, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $105 → $96 | $38.44 | +149.74% | 19 | Mar 2, 2026 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $120 → $113 | $46.86 | +141.14% | 12 | Feb 27, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $102 → $112 | $103.37 | +8.35% | 14 | Feb 26, 2026 | |
| SION Sionna Therapeutics | Initiates: Market Outperform | $63 | $41.06 | +53.43% | 1 | Feb 24, 2026 | |
| QNCX Quince Therapeutics | Downgrades: Market Perform | n/a | $1.39 | - | 3 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $527 → $745 | $520.61 | +43.10% | 15 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $35 | $5.94 | +489.72% | 9 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $11 → $10 | $4.99 | +100.40% | 10 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $14 | $2.81 | +399.11% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $27 → $25 | $8.85 | +182.49% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $6.03 | +231.67% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $9.45 | +206.88% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $4.39 | +310.02% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $28.78 | +80.71% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.65 | +384.85% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $0.83 | +1,705.92% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $7.32 | +159.56% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $33.24 | +14.32% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $45.97 | +8.77% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $36.86 | +144.17% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $141.68 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $504.59 | -3.88% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $64 | $8.59 | +645.05% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $28.72 | -16.43% | 1 | May 12, 2023 |
Mirum Pharmaceuticals
Apr 21, 2026
Reiterates: Market Outperform
Price Target: $132
Current: $92.01
Upside: +43.47%
DBV Technologies
Mar 27, 2026
Maintains: Market Outperform
Price Target: $45 → $47
Current: $19.50
Upside: +141.03%
KalVista Pharmaceuticals
Mar 26, 2026
Maintains: Market Outperform
Price Target: $29 → $28
Current: $18.79
Upside: +49.02%
Rhythm Pharmaceuticals
Mar 20, 2026
Maintains: Market Outperform
Price Target: $152 → $155
Current: $85.70
Upside: +80.86%
Spruce Biosciences
Mar 10, 2026
Maintains: Market Outperform
Price Target: $180 → $170
Current: $54.21
Upside: +213.60%
Crinetics Pharmaceuticals
Mar 2, 2026
Maintains: Market Outperform
Price Target: $105 → $96
Current: $38.44
Upside: +149.74%
Structure Therapeutics
Feb 27, 2026
Maintains: Market Outperform
Price Target: $120 → $113
Current: $46.86
Upside: +141.14%
Protagonist Therapeutics
Feb 26, 2026
Maintains: Market Outperform
Price Target: $102 → $112
Current: $103.37
Upside: +8.35%
Sionna Therapeutics
Feb 24, 2026
Initiates: Market Outperform
Price Target: $63
Current: $41.06
Upside: +53.43%
Quince Therapeutics
Jan 30, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $1.39
Upside: -
Jan 20, 2026
Maintains: Market Outperform
Price Target: $527 → $745
Current: $520.61
Upside: +43.10%
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $5.94
Upside: +489.72%
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $4.99
Upside: +100.40%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $2.81
Upside: +399.11%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $8.85
Upside: +182.49%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $6.03
Upside: +231.67%
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $9.45
Upside: +206.88%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $4.39
Upside: +310.02%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $28.78
Upside: +80.71%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $1.65
Upside: +384.85%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $0.83
Upside: +1,705.92%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $7.32
Upside: +159.56%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $33.24
Upside: +14.32%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $45.97
Upside: +8.77%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $36.86
Upside: +144.17%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $141.68
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $504.59
Upside: -3.88%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $64
Current: $8.59
Upside: +645.05%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $28.72
Upside: -16.43%